Information Provided By:
Fly News Breaks for March 29, 2018
TBPH
Mar 29, 2018 | 05:01 EDT
Piper Jaffray analyst Tyler Van Buren assumed coverage of Theravance Biopharma with an Overweight rating and $45 price target. The company's respiratory products Trelegy and revefenacin "provide solid valuation support with the potential for significant upside" from its proprietary 1473/JAK and 9855/nOH development candidate, the analyst contends. He has confidence in the Trelegy launch and revefenacin approval and recommends investors buy the shares.
News For TBPH From the Last 2 Days
There are no results for your query TBPH